Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel

Aurelius Omlin; Oliver Sartor; Christian Rothermundt; Richard Cathomas; Johann S De Bono; Liji Shen; Zhen Su; Silke Gillessen

doi:10.1016/j.clgc.2015.01.010

Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel

Aurelius Omlin, Oliver Sartor, Christian Rothermundt, Richard Cathomas, Johann S De Bono, Liji Shen, Zhen Su, Silke Gillessen

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

INTRODUCTION: We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel.

MATERIALS AND METHODS: Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel every 3 weeks (q3w) (in TAX327 and VENICE) and cabazitaxel q3w (in TROPIC) were analyzed.

RESULTS: The frequency of new or worsening AEs (all G and G3-4) for 1301 patients was significantly less for alopecia, nail changes, neuropathy, and dysgeusia for cabazitaxel compared with docetaxel.

CONCLUSION: Treatment with cabazitaxel might cause less alopecia, nail changes, neuropathy, and dysgeusia compared with docetaxel.

Original language	English
Pages (from-to)	e205-e208
Journal	Clinical Genitourinary Cancer
Volume	13
Issue number	4
DOIs	https://doi.org/10.1016/j.clgc.2015.01.010
Publication status	Published - Aug 2015

Keywords

Alopecia/epidemiology
Clinical Trials as Topic
Docetaxel
Drug-Related Side Effects and Adverse Reactions/epidemiology
Dysgeusia/epidemiology
Humans
Male
Nail Diseases/epidemiology
Peripheral Nervous System Diseases/epidemiology
Prospective Studies
Prostatic Neoplasms/drug therapy
Retrospective Studies
Taxoids/administration & dosage

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clgc.2015.01.010

Cite this

@article{679553cee16f4a43a6086abcce6cedaa,

title = "Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel",

abstract = "INTRODUCTION: We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel.MATERIALS AND METHODS: Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel every 3 weeks (q3w) (in TAX327 and VENICE) and cabazitaxel q3w (in TROPIC) were analyzed.RESULTS: The frequency of new or worsening AEs (all G and G3-4) for 1301 patients was significantly less for alopecia, nail changes, neuropathy, and dysgeusia for cabazitaxel compared with docetaxel.CONCLUSION: Treatment with cabazitaxel might cause less alopecia, nail changes, neuropathy, and dysgeusia compared with docetaxel.",

keywords = "Alopecia/epidemiology, Clinical Trials as Topic, Docetaxel, Drug-Related Side Effects and Adverse Reactions/epidemiology, Dysgeusia/epidemiology, Humans, Male, Nail Diseases/epidemiology, Peripheral Nervous System Diseases/epidemiology, Prospective Studies, Prostatic Neoplasms/drug therapy, Retrospective Studies, Taxoids/administration & dosage",

author = "Aurelius Omlin and Oliver Sartor and Christian Rothermundt and Richard Cathomas and {De Bono}, {Johann S} and Liji Shen and Zhen Su and Silke Gillessen",

year = "2015",

month = aug,

doi = "10.1016/j.clgc.2015.01.010",

language = "English",

volume = "13",

pages = "e205--e208",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier BV",

number = "4",

}

Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. / Omlin, Aurelius; Sartor, Oliver; Rothermundt, Christian et al.
In: Clinical Genitourinary Cancer, Vol. 13, No. 4, 08.2015, p. e205-e208.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel

AU - Omlin, Aurelius

AU - Sartor, Oliver

AU - Rothermundt, Christian

AU - Cathomas, Richard

AU - De Bono, Johann S

AU - Shen, Liji

AU - Su, Zhen

AU - Gillessen, Silke

PY - 2015/8

Y1 - 2015/8

N2 - INTRODUCTION: We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel.MATERIALS AND METHODS: Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel every 3 weeks (q3w) (in TAX327 and VENICE) and cabazitaxel q3w (in TROPIC) were analyzed.RESULTS: The frequency of new or worsening AEs (all G and G3-4) for 1301 patients was significantly less for alopecia, nail changes, neuropathy, and dysgeusia for cabazitaxel compared with docetaxel.CONCLUSION: Treatment with cabazitaxel might cause less alopecia, nail changes, neuropathy, and dysgeusia compared with docetaxel.

AB - INTRODUCTION: We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel.MATERIALS AND METHODS: Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel every 3 weeks (q3w) (in TAX327 and VENICE) and cabazitaxel q3w (in TROPIC) were analyzed.RESULTS: The frequency of new or worsening AEs (all G and G3-4) for 1301 patients was significantly less for alopecia, nail changes, neuropathy, and dysgeusia for cabazitaxel compared with docetaxel.CONCLUSION: Treatment with cabazitaxel might cause less alopecia, nail changes, neuropathy, and dysgeusia compared with docetaxel.

KW - Alopecia/epidemiology

KW - Clinical Trials as Topic

KW - Docetaxel

KW - Drug-Related Side Effects and Adverse Reactions/epidemiology

KW - Dysgeusia/epidemiology

KW - Humans

KW - Male

KW - Nail Diseases/epidemiology

KW - Peripheral Nervous System Diseases/epidemiology

KW - Prospective Studies

KW - Prostatic Neoplasms/drug therapy

KW - Retrospective Studies

KW - Taxoids/administration & dosage

U2 - 10.1016/j.clgc.2015.01.010

DO - 10.1016/j.clgc.2015.01.010

M3 - Article

C2 - 25733056

SN - 1558-7673

VL - 13

SP - e205-e208

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 4

ER -

Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this